SPOTLIGHT: Immtech announce Phase III analysis

Immtech Pharmaceuticals announced that following the evaluation of data from interim Phase III trial, an independent data safety monitoring board recommended to continue the trial of pafuramidine as planned. Pafuramidine is an oral treatment for Human African Tryanosomiasis (African sleeping sickness), a fatal, parasitic disease spread by tsetse flies. Results from the Phase III trial are expected in the second quarter of 2008. Release

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.